Researchers uncover molecular drivers of a deadly pediatric cancer

Researchers from Cincinnati Children’s Hospital have made important discoveries about the molecular mechanisms driving acute myeloid leukemia (AML), a deadly pediatric cancer. The findings could lead to the development of new treatments.

MLL-AF9 Leukemia Cells. (Image Credit: Cincinnati Children's)

Writing in the Journal of Experimental Medicine, the scientists refer to their findings as representing “a new opportunity for AML therapeutics."

Acute myeloid leukemia is a deadly blood cancer associated with a survival rate of only 20 to 40%and improved treatment approaches are urgently needed.

AML arises when a defect on the chromosome 11q23 changes how white blood cells are genetically programmed, by causing a fusion of harmful genes that makes the cells cancerous.

Now, Leighton Grimes (principal investigator and director of Cancer Pathology at the Cincinnati Children’s) and colleagues have identified a potential new molecular target for treating the illness.

Working with mice and donated human cells from patients, the team were able to identify a target molecule found on the surface of human AML cells.

They found that when they blocked this molecule in combination with existing AML therapies, the cancerous white blood cells were replaced by healthy, regenerating cells.

The therapeutic target is a molecule called S-phase kinase-associated protein 2 (Skp2). This protein degrades another molecule − p27Kip1 − that is required for the formation of healthy blood cells.

Our work provides a complete mechanistic look into the function of genetic and molecular programs driving this leukemia, and it exploits these processes to identify actionable therapeutic targets.”

Leighton Grimes, Principal Investigator

He adds that the approach is not yet ready for clinical application, saying: "We still have extensive additional testing to conduct in laboratory animal models of AML before knowing if this approach will translate to patient care."

Despite the additional work that is needed, the findings do suggest that it may be possible to develop effective treatments for AML, concludes Grimes.

Source:

https://www.eurekalert.org/pub_releases/2018-07/cchm-taf070918.php

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Researchers uncover molecular drivers of a deadly pediatric cancer. News-Medical. Retrieved on October 10, 2024 from https://www.news-medical.net/news/20180711/Researchers-uncover-molecular-drivers-of-a-deadly-pediatric-cancer.aspx.

  • MLA

    Robertson, Sally. "Researchers uncover molecular drivers of a deadly pediatric cancer". News-Medical. 10 October 2024. <https://www.news-medical.net/news/20180711/Researchers-uncover-molecular-drivers-of-a-deadly-pediatric-cancer.aspx>.

  • Chicago

    Robertson, Sally. "Researchers uncover molecular drivers of a deadly pediatric cancer". News-Medical. https://www.news-medical.net/news/20180711/Researchers-uncover-molecular-drivers-of-a-deadly-pediatric-cancer.aspx. (accessed October 10, 2024).

  • Harvard

    Robertson, Sally. 2018. Researchers uncover molecular drivers of a deadly pediatric cancer. News-Medical, viewed 10 October 2024, https://www.news-medical.net/news/20180711/Researchers-uncover-molecular-drivers-of-a-deadly-pediatric-cancer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Jefferson Lab team explores proton therapy as a safer cancer treatment